RBX7455 Oral Clostridium difficile Prevention

Rebiotix is leveraging it clinical and regulatory experience with RBX2660 to develop an oral Microbiota Restoration Therapy™ (MRT™) drug platform targeted at Clostridium difficile (C. diff.) infection prevention.

About RBX7455

  • Oral MRT will enable easier application for repeat dosing
  • Lyophilized formulation
  • Room temperature stability
  • Broad spectrum gut microbiota
  • Master File submitted to the U.S. Food and Drug Administration
  • First human clinical study began Q4 2016
RBX7455 Oral Clostridium difficile Prevention Rebiotix